Article Text

Download PDFPDF
Review: buprenorphine better than α2 adrenergic agonists for managing opioid withdrawal

Statistics from Altmetric.com

Footnotes

  • Sources of funding Drug and Alcohol Services South Australia and the Commonwealth Department of Health and Ageing, Australia.

Footnotes

  • Competing interests JM is a paid consultant and leads teaching programmes for Reckitt Benckiser, the manufacturer of buprenorphine.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles